Tislelizumab
Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody designed with an Fc region modification to eliminate FcγR binding and minimize antibody-dependent cellular phagocytosis of T cells, restoring anti-tumor immune responses by blocking PD-1/PD-L1 and PD-1/PD-L2 checkpoint interactions. It is approved in multiple countries for various cancers including classical Hodgkin lymphoma, urothelial carcinoma, and esophageal cancer, and is under investigation for other indications. Its unique Fc engineering differentiates it from other anti-PD-1 antibodies.
ด้านการรักษา
กลไกการออกฤทธิ์
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
คำถามที่พบบ่อย
Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody designed with an Fc region modification to eliminate FcγR binding and minimize antibody-dependent cellular phagocytosis of T cells, restoring anti-tumor immune responses by blocking PD-1/PD-L1 and PD-1/PD-L2 checkpoint interactions. It is approved in multiple countries for various cancers including classical Hodgkin lymphoma, urothelial carcinoma, and esophageal cancer, and is under investigation for other indications. Its unique Fc engineering differentiates it from other anti-PD-1 antibodies.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Tislelizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297840. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
ข้อจำกัดความรับผิดชอบทางการแพทย์
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tislelizumab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tislelizumab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tislelizumab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tislelizumab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tislelizumab"></drugfyi-drug>